August 2010
This Issue's Articles
Reflections on the past 15 years in the industry.
by: Don Powers
Examining the various market forces shaping the IVD industry and its supporting instrumentation.
by: Warren Hancock
Reviewing the key trends that have emerged in the ways that assays
are developed.
by: Kevin Jones
The field has matured since 1995. The challenge that remains is to improve clinical utility.
by: Joel A. Lefferts and Gregory J. Tsongalis
Examining the changes and developments in point-of-care testing technologies during the past 15 years.
by: Steve Ross
When looking back, one finds that the rules have changed little, but regulation has changed a great deal.
by: Jeffrey N. Gibbs
Heavy regulatory change begun in the 1990s has continued right up through 2010.
by: Petra Kaars-Wiele
Will pharma ever believe the costs and limitations of developing drugs that require companion diagnostics are worthwhile?
by: Richard S. Schifreen
A maturing IVD industry has been moving toward more medically actionable tests, services, and technologies.
by: Shara Rosen
Examining advanced detection technologies for IVDs and molecular diagnostics.
by: Amit Kumar, Brooke P. Anderson, and Kilian Dill
Industry executives and thought leaders speculate on what challenges and opportunities lay ahead for the IVD industry during the next 15 years.